The stock got approved.
Then it dropped.

1. Buy the Rumor, Sell the News

This is the most common and most painful dynamic in biotech. Here's how it works: a drug moves through clinical development, and at each stage — positive Phase 2 data, breakthrough therapy designation, Phase 3 success, FDA filing acceptance — the stock re-prices upward. Each milestone increases the probability of approval, and the market adjusts accordingly. By the time the actual PDUFA date arrives, the approval probability might be 85-95%. The approval doesn't add new information — it just removes the last 5-15% of uncertainty.

The traders who bought at Phase 2 data now have 200-400% gains. The approval is their exit signal, not their entry point. They were buying the rumor (the probability of approval), and now they're selling the news (the confirmation). The stock doesn't need to go down for them to profit. It just needs to stop going up.

2. The Pre-Catalyst Run-Up Trap

This is the timing version of the buy-the-rumor problem, and it catches traders who do the right analysis but enter at the wrong time.

In the 4-6 weeks before a high-profile PDUFA date, biotech stocks typically experience a "run-up" as momentum traders, event-driven hedge funds, and retail buyers pile in. The logic is simple: if there's a 70-90% chance of approval, the risk/reward looks favorable. But when everyone thinks this way simultaneously, the pre-catalyst buying creates its own gravity. The stock runs 20-40% into the catalyst date.

Now the math changes. If the stock is up 35% heading into a PDUFA with 85% approval probability, the expected value of holding through the event is much lower than it appears. The approval scenario (85% probability) might yield another 10-15% upside — because the run-up already captured most of the move. The rejection scenario (15% probability) could mean a 50-70% crash. The asymmetry has flipped. The same trade that was positive expected value six weeks ago is now negative expected value on the eve of the decision.

This is why you see "sell the news" even on approvals. Sophisticated traders who rode the run-up are locking in gains at the exact moment retail traders are FOMOing in. The approval removes the uncertainty that was fueling the momentum trade. Without uncertainty, there's no premium for holding.

3. The Dilution Trap: When Good News Means More Shares

This is the one that makes retail traders the angriest, because it feels like betrayal. The company gets positive data. The stock pops. And within days or weeks, the company announces a secondary offering, a PIPE deal, or activates an ATM (at-the-market) program to sell new shares into the market. Your position gets diluted. The stock gives back most or all of the catalyst gains.

Here's the thing: this isn't a betrayal. It's the business model. Clinical-stage biotechs burn cash. They don't have revenue. They need capital to fund the next trial, build manufacturing, hire a commercial team, and launch the drug. Positive data creates a window where the stock price is elevated and investor appetite is high — that's the optimal time to raise capital. Management would be negligent not to raise money when the market is willing to give it to them at a favorable price.

4. Priced to Perfection: Anything Less Is a Sell

Sometimes a stock runs up so aggressively before a catalyst that the market has essentially priced in the best possible outcome. Not just approval — but approval with a broad label, no REMS requirements, no black box warning, and peak sales estimates at the high end of analyst projections. When the actual outcome arrives and it's merely "good" instead of "perfect," the stock corrects.

This is different from buy-the-rumor. In that dynamic, the stock drops because the event was expected. In the priced-to-perfection dynamic, the stock drops because the event was expected to be better than it was.

Watch for this dynamic especially in competitive therapeutic categories. If the market is modeling your drug as a first-line treatment and the FDA approves it as second-line only, that's a smaller patient population and lower peak sales. If the label requires a REMS program or carries a black box warning, prescribers may hesitate. The FDA's 74% first-cycle approval rate in 2024 sounds reassuring — but the 26% that get Complete Response Letters, and the many more that get approvals with label restrictions, can devastate stocks that were priced for perfection.

5. The Competitor Shadow

Your drug's catalyst doesn't exist in a vacuum. The same week your company reports positive Phase 3 data, a competitor might report better data in the same indication. A larger pharma company might announce they're entering the space. A generic or biosimilar might get FDA approval for the incumbent product. Your data can be objectively good and still send the stock down because the competitive landscape shifted.

This dynamic is particularly brutal in crowded therapeutic areas like oncology, autoimmune disease, and metabolic conditions. When four companies are all running Phase 3 trials for the same indication, the commercial pie doesn't grow proportionally with each new entrant. It gets divided. Each positive readout for a competitor compresses your drug's expected market share, even if your drug's data is also positive.

Putting It All Together: The Catalyst Trading Framework

Understanding these five dynamics doesn't mean avoiding biotech catalysts. It means approaching them with a framework that accounts for the full picture — not just the science, but the market mechanics around it.

Bio-Score measures the magnitude of expected volatility around a catalyst. That volatility is real. But volatility is directionless — it cuts both ways. These five dynamics explain why a high Bio-Score catalyst can produce a massive move down even on objectively positive news. The score tells you the powder keg is loaded. This framework helps you figure out which way the fuse is burning.